Abstract
With the assumption of the validity of the Hardin Jones principle that the death rate of members of a homogeneous cohort of cancer patients is constant, three criteria for the validity of clinical trials of cancer treatments are formulated. These criteria are satisfied by most published clinical trials, but one trial was found to violate all three, rendering the validity of its reported results uncertain.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cameron E., Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1976 Oct;73(10):3685–3689. doi: 10.1073/pnas.73.10.3685. [DOI] [PMC free article] [PubMed] [Google Scholar]
- JONES H. B. Demographic consideration of the cancer problem. Trans N Y Acad Sci. 1956 Feb;18(4):298–333. doi: 10.1111/j.2164-0947.1956.tb00453.x. [DOI] [PubMed] [Google Scholar]
- Moertel C. G., Fleming T. R., Creagan E. T., Rubin J., O'Connell M. J., Ames M. M. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med. 1985 Jan 17;312(3):137–141. doi: 10.1056/NEJM198501173120301. [DOI] [PubMed] [Google Scholar]
- Pauling L. Biostatistical analysis of mortality data for cohorts of cancer patients. Proc Natl Acad Sci U S A. 1989 May;86(10):3466–3468. doi: 10.1073/pnas.86.10.3466. [DOI] [PMC free article] [PubMed] [Google Scholar]